Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

TZ9, Rad6 Ubiquitin Inhibitor

TZ9, Rad6 Ubiquitin Inhibitor

$109.00
A selective and cell permeable inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B.
Catalog No. Unit Price Qty
M60286-2s 2 mg solid $109.00

Details

Product Information
Molecular Weight: 366.34
Formula: C17H14N6O4
Purity: ≥98%
CAS#: 1002789-86-7
Solubility: DMSO up to 50 mM
Chemical Name: (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

TZ9 is a selective and cell permeable inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B. It binds to the Rad6B catalytic site, inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin. It can induce G2/M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells (IC50 ~6 µM).

How to Use:

In vitro: TZ9 was used at 10-50 µM final concentration in vitro and in cellular assays.
In vivo: n/a


Reference:

  • 1. Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. (2013) Mol Cancer Ther. 12(4):373-83.


TZ9_spec.pdf      
TZ9_MSDS.pdf      


Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 366.34
Formula: C17H14N6O4
Purity: ≥98%
CAS#: 1002789-86-7
Solubility: DMSO up to 50 mM
Chemical Name: (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

TZ9 is a selective and cell permeable inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B. It binds to the Rad6B catalytic site, inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin. It can induce G2/M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells (IC50 ~6 µM).

How to Use:

In vitro: TZ9 was used at 10-50 µM final concentration in vitro and in cellular assays.
In vivo: n/a


Reference:

  • 1. Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. (2013) Mol Cancer Ther. 12(4):373-83.


TZ9_spec.pdf      
TZ9_MSDS.pdf      


Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: